Clinical Trial Detail

NCT ID NCT02580708
Title A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

non-small cell lung carcinoma

Therapies

Trametinib

Rociletinib

Age Groups: adult

Additional content available in CKB BOOST